Novartis Predicts $4 Billion Peak Sales For Gleevec/Tasigna Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib’s side-effect profile over Bristol’s Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says.